These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Equivalency of drugs and the problem of biological availability]. Hirtz J Rev Prat; 1973 Nov; 23(53):7-10. PubMed ID: 4802222 [No Abstract] [Full Text] [Related]
26. Repeated-measures bioassay with correlated errors and heterogeneous variances: a Monte Carlo study. Elashoff JD Biometrics; 1981 Sep; 37(3):475-82. PubMed ID: 7317557 [TBL] [Abstract][Full Text] [Related]
27. Generic-therapeutic equivalence--enigma or myth? Shirkey HC Hawaii Med J; 1970; 29(3):201-2. PubMed ID: 5416016 [No Abstract] [Full Text] [Related]
28. [Revalidation of the in vitro specification limits after an in vitro-in vivo correlation]. Pabst G Arzneimittelforschung; 1998 May; 48(5A):584-8. PubMed ID: 9676349 [TBL] [Abstract][Full Text] [Related]
29. Tests for equivalence or non-inferiority--why? Drug Ther Bull; 2008 Jul; 46(7):55-6. PubMed ID: 18603641 [TBL] [Abstract][Full Text] [Related]
30. [Chronotherapy: general principles]. Markiewicz A Pieleg Polozna; 1982; (4-5):4-5. PubMed ID: 6922558 [No Abstract] [Full Text] [Related]
31. In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption. del Amo EM; Heikkinen AT; Mönkkönen J Eur J Pharm Sci; 2009 Feb; 36(2-3):200-11. PubMed ID: 19063964 [TBL] [Abstract][Full Text] [Related]
32. [Comparative biopharmaceutical study of tegalide]. Lopatina NB; Lebedeva MN Med Parazitol (Mosk); 2000; (1):27-9. PubMed ID: 10808715 [TBL] [Abstract][Full Text] [Related]
33. Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations. Halsas M; Penttinen T; Veski P; Jürjenson H; Marvola M Pharmazie; 2001 Sep; 56(9):718-23. PubMed ID: 11593992 [TBL] [Abstract][Full Text] [Related]
34. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption. Dunne A; O'Hara T; Devane J Stat Med; 1999 Jul; 18(14):1865-76; discussion 1877. PubMed ID: 10407257 [TBL] [Abstract][Full Text] [Related]
35. Equivalence of various levothyroxine preparations. Fischer RG; Kibbe AH; Nicholas WC; Sbravati C; Read VH J Fam Pract; 1982 Mar; 14(3):591-3. PubMed ID: 7038029 [No Abstract] [Full Text] [Related]
36. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. Dahan A; Hoffman A J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294 [TBL] [Abstract][Full Text] [Related]
37. [Recent advance in predicting oral bioavailability]. Ma GL; Cheng YY Yao Xue Xue Bao; 2006 Oct; 41(10):917-20. PubMed ID: 17184106 [No Abstract] [Full Text] [Related]
38. A time to speak out on bioequivalence and therapeutic equivalence. Dettelbach HR J Clin Pharmacol; 1986; 26(5):307-8. PubMed ID: 2871052 [No Abstract] [Full Text] [Related]
39. In vitro - in vivo correlation: from theory to applications. Emami J J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187 [TBL] [Abstract][Full Text] [Related]
40. The pharmaceutical and biological availability of commercial preparations of furosemide. Stüber W; Mutschler E; Steinbach D Arzneimittelforschung; 1982; 32(6):693-7. PubMed ID: 6889429 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]